This dataset present information on the age-sex specific incidence rate of multiple sclerosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

This statistic shows the number of individuals with multiple sclerosis in the United Kingdom in 2014, by country. In this year, over 107.7 thousand individuals in the United Kingdom had multiple sclerosis.

Background: Multiple sclerosis (MS) is one of the most common neurological disorders and a leading cause of nontraumatic disability in young adults in many countries. Recent reports from the Middle East and North Africa have suggested a moderate to high risk of MS in these countries. Methods: A literature search was performed in August 2014 in MEDLINE, EMBASE, and IMEMR to retrieve original population-based studies on MS epidemiology in the Middle East and North African countries published between 1st January 1985 and 1st August 2014. We designed search strategies using the key words: MS, prevalence, incidence, and epidemiology. According to the inclusion criteria, 52 studies were included in this systematic review. Results: McDonald's criteria were the most widely used diagnostic criteria in the studies. Most studies were conducted in single hospital-based centers with a defined catchment area. The female/male ratio ranged from 0.8 in Oman to 4.3 in Saudi Arabia. MS prevalence ranged from 14.77/100,000 population in Kuwait (2000) to 101.4/100,000 in Turkey (2006). The overall MS prevalence in the region was 51.52/100,000. The mean age at disease onset ranged from 25.2 years in Kuwait to 32.5 years in Northeastern Iran, with an overall estimate of 28.54 years. Conclusions: Recent advances in MS registries will allow nation-wide studies and temporal comparisons between countries, provided that age- and sex-standardized estimates are available.

AbstractObjective: To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets. Methods: A validated algorithm was applied to private, military, and public AHC datasets to identify adult cases of MS between 2008 and 2010. In each dataset, we determined the 3-year cumulative prevalence overall and stratified by age, sex, and census region. We applied insurance-specific and stratum-specific estimates to the 2010 US Census data and pooled the findings to calculate the 2010 prevalence of MS in the United States cumulated over 3 years. We also estimated the 2010 prevalence cumulated over 10 years using 2 models and extrapolated our estimate to 2017. Results: The estimated 2010 prevalence of MS in the US adult population cumulated over 10 years was 309.2 per 100,000 (95% confidence interval [CI] 308.1–310.1), representing 727,344 cases. During the same time period, the MS prevalence was 450.1 per 100,000 (95% CI 448.1–451.6) for women and 159.7 (95% CI 158.7–160.6) for men (female:male ratio 2.8). The estimated 2010 prevalence of MS was highest in the 55- to 64-year age group. A US north-south decreasing prevalence gradient was identified. The estimated MS prevalence is also presented for 2017. Conclusion: The estimated US national MS prevalence for 2010 is the highest reported to date and provides evidence that the north-south gradient persists. Our rigorous algorithm-based approach to estimating prevalence is efficient and has the potential to be used for other chronic neurologic conditions. Usage notesPrev of MS in the US-E-Appendix-Feb-19-2018

In the fiscal year *********, around *** percent of adults aged 20 years and older in Canada suffered from multiple sclerosis. At that time, the prevalence of multiple sclerosis was highest in Saskatchewan. This statistic illustrates the prevalence of multiple sclerosis among adults 20 years and older in Canada in *********, by province and territory.

Introduction: Understanding the prevalence of multiple sclerosis (MS) provides information for healthcare planning and helps identify trends and patterns of disease occurrence. For Switzerland, the number of persons with MS (pwMS) was last estimated at approximately 15,000 in 2016. The study’s objectives are to update estimates of MS prevalence and characterise the change in MS prevalence in Switzerland between 2016 and 2021, the last year with complete administrative data.

Methods: The Swiss MS Registry (SMSR) is an ongoing, longitudinal study in Switzerland. It has previously established a methodology to assess the epidemiology of MS in Switzerland by integrating SMSR data with administrative data on reimbursement approvals for disease-modifying therapies (DMTs). Subsequently, the benchmark-multiplier method is applied to the combined data. Using the same methodology, we calculated overall and sex- and age-specific prevalence rates for 2021. Furthermore, we descriptively analysed changes since 2016 by comparing the prevalence figures and demographic and clinical characteristics of pwMS in both years.

Results: We estimated the population of pwMS in Switzerland at 18,140 [95% simulation interval 17,550-18,750], corresponding to a period prevalence of 200.8-214.5/100,000 inhabitants. Peak prevalence was observed in the 50 to 55-year age group. Compared to 2016, the 2021 estimate corresponds to a 20% increase (n=3,000). Extrapolating from Swiss population growth, we estimated that one-fifth of the observed prevalence increase may be attributed to a rising population. The proportion of pwMS in the age range from 50 to 64 (32.5% vs. 35.9%) and above 65 (8.0% vs. 11.1%) years increased. Consequently, the median [interquartile range] age increased from 47 [37-55] to 49 [38-57] years. The median age at diagnosis (36 [28-45] years) and the female-to-male ratio (2.7:1) remained stable since 2016. The proportion of pwMS treated with DMTs increased from 62.1% to 69.0%, with the largest change observed in infusion therapies (15.7% vs. 23.3%).

Conclusion: The estimated MS prevalence in Switzerland has increased since the previous estimate in 2016, with a shift in peak prevalence towards older ages. Population growth explained around one-fifth of this increase, thus leaving room for contributions by additional factors, which require further investigation. The rising MS prevalence has several implications for healthcare, research and society.

The countries with the highest prevalence of multiple sclerosis include Canada, San Marino, Denmark, and Sweden. Multiple sclerosis (MS) is a disease that affects communication in parts of the nervous system and damages the brain and spinal cord. Some of those with MS eventually become disabled due to the disease, but many can still walk, if not with the aid of a cane or crutches.

Symptoms

Symptoms of MS frequently affect movement, and can cause vision problems, slurred speech, fatigue, and trouble with coordination. Symptoms can vary greatly from person to person and people with MS may experience periods where symptoms improve partially or completely and then relapse. The most common symptoms that keep those with MS from working include fatigue, difficulty walking, standing and moving around, weakness, and cognitive impairment.

Impact of MS

Multiple sclerosis can impact the lives of those living with the disease in many ways. A survey from 2018 of people suffering from MS found that 24 percent stated they had chosen to stop working due to the disease, while 13 percent lost their job and 12 percent had to take medical leave. MS can also impact the personal and intimate lives of those who suffer. The same survey found 38 percent of respondents said fatigue from MS negatively impacted their sex life.

PP = progressive-relapsing multiple sclerosis; RR = relapsing-remitting multiple sclerosis; SP = secondary-progressive multiple sclerosis. F = female;M = male.

This dataset present information on the age-standardized prevalence rate of multiple sclerosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

Snapshot img { margin: 10px !important; }

Industry Insights

The global multiple sclerosis drugs market size will grow by USD 7.79 billion during 2019-2023 at a CAGR of close to 6%. The rising prevalence of multiple sclerosis and the development of novel drugs are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by type (oral and parenteral) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Bayer AG, Biogen, Merck KGaA, Novartis AG, and Sanofi.

Key Insights from Multiple Sclerosis Drugs Market – Global Forecast 2019-2023

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the multiple sclerosis drugs market report

Request a FREE sample now!

The rising prevalence of multiple sclerosis is one of the key factors expected to trigger multiple sclerosis drugs market growth in the coming years. Several factors including genetic and environmental are contributing to the rising incidence of multiple sclerosis. Prevalence of autoimmune diseases, including type 1 diabetes and certain infections, including the infectious mononucleosis also lead to a surging risk of multiple sclerosis. With the rising incidence of this health condition, the demand for MS drugs will increase significantly in the coming years which will contribute to the growth of multiple sclerosis drugs market size.

The development of novel drugs is one of the key trends expected to gain traction in the market. Researchers have already discovered drugs that slow the progression of the symptoms of secondary progressive multiple sclerosis. Furthermore, the market has also witnessed increased approvals of innovative therapies for the treatment of relapsing forms of multiple sclerosis and primary-progressive multiple sclerosis. The rising development of novel drugs coupled with the growing prevalence of the disease will drive the multiple sclerosis drugs market growth at a CAGR of close to 6% during the forecast period.

Industry Analysis

    <ul>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market size for 2018</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market forecast for 2019 to 2023</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Regional market opportunities</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market segment opportunities</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Growth momentum: Overall market and individual market segments</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market condition: 2018</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market segmentation based on type: oral and parenteral</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market size, market forecast, and growth momentum</li>
      <li style="margin-bottom:0in;margin-bottom:.0001pt;">Market size and forecast in

This statistic shows the number of individuals with multiple sclerosis in the United Kingdom in 2014, by age and gender. In 2014 over 22 thousand women aged between 50 and 59 years had multiple sclerosis.

Background: When population-based databases are unavailable, nationwide assessments of the disease burden of multiple sclerosis (MS) resort to clinical, administrative or convenience-sampled data sources, which may produce results of limited external validity. Our aim was to develop a framework for estimating measures of occurrence of chronic diseases, and more broadly disease burden, that mitigate these limitations and to apply this framework to estimate the prevalence of multiple sclerosis (MS) in Switzerland.Methods: We developed a 7-step framework which implements the combination of several data sources together with a resampling and critical appraisal approach. The framework was applied to estimate the MS prevalence for 2016 in Switzerland, for which four distinct data sources (Swiss MS registry, Swiss national MS treatment registry, MediService database, and Swiss MS cohort study) were combined. Results were reviewed by disease experts and compared to earlier Swiss estimates and current prevalence estimates from other countries.Results: We estimate that in the year 2016 between 14,650 and 15,700 persons with MS have been living in Switzerland, yielding a period prevalence of 174–187/100,000 inhabitants. Compared to the last estimate in 1986, we detected a substantial increase of MS diagnoses which coincides with a higher number of diagnoses in women below the age of 65.Conclusions: Internationally, Switzerland is a high-prevalence country for MS, although estimates were somewhat lower than recent evaluations of Northern European countries. In addition, we corroborate previous reports that the prevalence increase coincides with a higher number of MS diagnoses among women. The proposed framework has wide applicability and the potential to place estimates of disease occurrence and burden with imperfect data availability on more solid grounds.

Demographic, clinical and laboratory findings of neuromyelitis optica (NMO) and multiple sclerosis (MS) Brazilian patients.

ABSTRACT Background: To improve the comparability of multiple sclerosis (MS) prevalence across Brazilian regions, the Brazilian Committee for Treatment and Research in MS has implemented a standardized approach to assess the prevalence of the disease in five key cities, which were deemed representative of their regions in terms of socio-geographical features and where in-person revision of each case was feasible. Objective: To report the point-prevalence of MS in Passo Fundo, one of the key cities in Southern Brazil. Methods: We sought to identify all MS patients who were living in Passo Fundo on July 1st, 2015. The primary source for case ascertainment was records from the offices of neurologists and neurosurgeons practicing in the city. Multiple secondary sources were used to maximize identification of cases. All patients underwent in-person review of the diagnosis by a panel of neurologists with experience in MS. Results: We identified 52 MS patients living in Passo Fundo on July 1st, 2015. The point-prevalence rate for MS was 26.4/100,000 population (95% confidence interval, 19.7 to 34.6/100,000). Among the MS cases, 42 (80.8%) were female, for a sex ratio of 4.2:1. Forty-six cases (88.5%) were categorized as relapsing-remitting MS, and the remaining 6 cases, as secondary progressive MS (11.5%). Other epidemiological and clinical features were comparable to national and international MS populations. Conclusions: The prevalence of MS in Passo Fundo is one of the highest reported in Brazil so far. Studies in other key Brazilian cities, using the same methodology, are currently being carried out.

The Multiple Sclerosis Treatment Market Report is Segmented by Drug Type (Large-Molecule Drugs and Small-Molecule Drugs), Route of Administration (Oral, Injectable, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

BackgroundPrevious genetic and epidemiological studies have examined subpopulations from the Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) patient cohort, but an encompassing analysis of the study population has not yet been carried out.ObjectiveThis retrospective study examines patterns of multiple sclerosis (MS) prevalence in 13,663 cohort members, including 4,821 persons with MS or suspected MS and 8,842 family members.MethodsWe grouped participants into epidemiologic subgroups based on age of MS onset, clinical stage at diagnosis, symptom type at disease onset, sex, proband status, disability as measured by the EDSS, and ancestry based on reported ethnicity.ResultsWe observed a 2.7:1 MS prevalence ratio of women to men, though disease severity was greater for male patients. Variation in the age of disease onset between patients was only slightly associated with sex and strongly associated with disease type. Specific types of clinical symptoms at disease onset were associated with the prognosis. Regional residence did not correlate with disease onset, type, or severity.ConclusionPopulation trends, as presented here, are not explained by environmental factors alone, highlighting the need for a comprehensive genetic analysis to understand disease variance across families.

According to Cognitive Market Research, The Multiple Sclerosis Treatment Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a USD XX million market size. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Multiple Sclerosis Treatment Market held the highest market revenue share in 2024. Market Dynamics of the Multiple Sclerosis Treatment Market

Key Drivers for The Multiple Sclerosis Treatment Market

Increased research funding, grants, and other investments for the drug development of multiple sclerosis research is projected to fuel the multiple sclerosis treatment market growth 

Major pharmaceutical firms are making significant investments in MS therapies' medication development process. To serve as many clients as possible, they intend to focus on as many indicators as they can. For example, the FDA authorized foralumab, a completely human intranasal anti-CD3 monoclonal antibody, in October 2023 for use as a medicine by individuals with multiple sclerosis (MS) who choose to self-administer it at home. Expanded uses for MS medications are also a key driver of the drug's increased use. For instance, in Feb 2022 for the treatment of relapsing forms of multiple sclerosis (RMS), Teva Pharmaceuticals Europe BV has verified that the SmPC for COPAXONE (Glatiramer Acetate (GA) injectable) in Europe is recommended at 20 mg/mL and 40 mg/ml. Health authorities in the European Union (EU) have officially authorized the product for use whilst nursing. Therefore, the development of innovative treatments and the recent approval of products by pharmaceutical firms are propelling market expansion. (https://www.tevapharm.com/news-and-media/latest-news/copaxone-label-now-indicates-its-use-in-breastfeeding-mothers-with-relapsing-multiple-sclerosis/)

Also, in Feb 2023 Menzies School of Health Research scientists won funds totaling USD 818,966 for their MS Research Flagship. Reducing the effects of multiple sclerosis (MS) on people and the community is the mission of MS Research Flagship. Because of this rising MS incidence as well as the numerous organic and inorganic operations of the major players, the market is anticipated to develop throughout the course of the projected period. Thus, increased investment in research and drug development fuel the market growth.

Thus, Increased research funding, grants, and investments in drug development for multiple sclerosis (MS) are anticipated to significantly boost advancements in treatment options. This influx of resources is expected to accelerate the discovery of novel therapies, improve existing treatments, and ultimately enhance patient outcomes. Consequently, the MS treatment market is poised for substantial growth as these developments translate into more effective and accessible solutions for individuals living with the condition.

Rising multiple sclerosis prevalence to drive the market for multiple sclerosis treatment 

The market for multiple sclerosis drugs is anticipated to rise in the future due to the rising prevalence of the disease. A chronic autoimmune illness that affects the central nervous system (CNS) and is frequently incapacitating is called multiple sclerosis (MS). Pharmaceuticals created to control and treat the signs and symptoms of multiple sclerosis (MS) are known as multiple sclerosis medications. These medications can help people with MS live better lives by reducing relapses, easing symptoms, and delaying the course of the illness. For instance, in May 2023 A report from the Indian hospital Pace Hospit...

SD = Standard Deviation; IQ = Interquartile Range; EDSS = Expanded Disability Status Scale; MSSS = Multiple Sclerosis Severity Score; FSS = Fatigue Severity Scale; DMD = Disease Modifying Drugs; ISA = immunosuppressive agents.

This statistic displays the distribution of inpatient multiple sclerosis cases in the United States by selected demographic group in 2012. In that year, **** percent of multiple sclerosis inpatient cases were male.

The Multiple Sclerosis (MS) treatment market presents a significant opportunity, with a market size of $17,370 million in 2025 and a projected Compound Annual Growth Rate (CAGR) of 1.9% from 2025 to 2033. This steady growth reflects the increasing prevalence of MS globally, coupled with ongoing advancements in disease-modifying therapies (DMTs). Key drivers include the rising number of MS diagnoses, particularly among younger populations, and the continuous development of more effective and safer treatment options targeting diverse MS subtypes. The market is characterized by intense competition among leading pharmaceutical companies such as Pfizer, Merck & Co, Teva Pharmaceutical, Sanofi, Bayer, Biogen, Roche, Novartis, CinnaGen, Mylan, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Acorda Therapeutics, each striving to innovate and capture market share. The development of novel therapies targeting specific disease mechanisms, alongside improved patient access to existing treatments, are projected to fuel market expansion. While challenges remain in addressing treatment limitations and variations in healthcare access across different regions, the overall outlook for the MS treatment market remains positive, driven by sustained R&D investment and unmet patient needs. The market segmentation, although not explicitly detailed, likely encompasses various DMT categories (e.g., interferons, glatiramer acetate, monoclonal antibodies, oral medications), reflecting different treatment approaches and patient profiles. Pricing strategies and reimbursement policies also play a crucial role in market dynamics. Geographic variations in disease prevalence and healthcare infrastructure influence regional market share, with North America and Europe currently holding significant portions. Future market growth will likely be influenced by the emergence of next-generation therapies with enhanced efficacy and safety profiles, along with factors such as increasing affordability and improved healthcare access in emerging markets. Understanding these multifaceted aspects is essential for navigating the complexities of this dynamic market.